$2.65-0.05 (-1.67%)
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
Rocket Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.65. Wall Street consensus targets $9.39 (11 analysts), implying a +253.5% move over the next 12 months. The stock is currently near its 52-week low of $2.40, remaining 25.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develo...
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) is one of the best gene therapy stocks to buy in 2026. The Street expects Rocket Pharmaceuticals’ stock to explode 180% over the next 12 months. On April 28, Leerink Partners boosted its price target on Rocket Pharmaceuticals shares to $12 from $11 while keeping a Market Perform rating on the […]
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best NASDAQ stocks under $5 to buy right now. On May 7, Rocket Pharmaceuticals reported a Q1 2026 net loss of $47.6 million ($0.42 per share). Driven by a recent realignment and lower headcount, R&D expenses fell to $31.5 million, and G&A expenses dropped to $17.1 million. […]
Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.
Rocket Pharmaceuticals' (RCKT) clinical and regulatory updates on its three cardiac gene therapy pro
The market has climbed 1.8% in the last 7 days and is up 30% over the past year, with earnings projected to grow by 16% annually. Penny stocks, while a somewhat outdated term, continue to represent intriguing investment opportunities for those looking beyond major corporations. With strong financial health and solid fundamentals, these smaller or newer companies can offer potential growth at lower price points.